In this video, Motley Fool health-care analyst David Williamson takes a closer look at Sarepta's big move on Friday. Wall Street is starting to wake up to this small biotech story and several key catalysts in the coming months could attract even more attention.
The Motley Fool's chief investment officer has selected his No. 1 stock for the next year. Find out which stock it is in our brand-new free report: "The Motley Fool's Top Stock for 2013." I invite you to take a copy, free for a limited time. Just click here to access the report and find out the name of this under-the-radar company.
The article Sarepta Adds Another Supporter originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. Follow him on Twitter @MotleyDavid. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.